Life
Briefing: What to Know About the BALANCE Model for GLP-1s in Medicare and Medicaid
Strategic angle: This brief describes current coverage of GLP-1s in Medicare and Medicaid, and CMS's efforts to expand access and lower costs through the BALANCE model.
Editorial Staff
1 min read
Updated 24 days ago
The Centers for Medicare & Medicaid Services (CMS) is currently overseeing the coverage of GLP-1 medications within Medicare and Medicaid programs. This coverage is crucial for managing diabetes and obesity.
To address access and affordability, CMS is implementing the BALANCE model, which comprises temporary demonstration programs designed to evaluate the effectiveness of GLP-1s in these populations.
The BALANCE model aims to provide insights into how expanded access to GLP-1s can lead to better health outcomes while simultaneously working to lower associated costs.